OpenAI-backed Chai Discovery raises $130 million for AI-designed molecules

Chai Discovery, an artificial intelligence drug-discovery company backed by OpenAI, has raised $130 million to build a “computer-aided design suite” for molecules.

The deal, which values the company at $1.3 billion, comes just three months after the startup’s last funding round and brings its total financing to $225 million. The Series B financing was co-led by Oak HC/FT and General Catalyst.

“Looking back over the last five to 10 years, there’s been so much hype on AI for drug discovery,” co-founder and Chief Executive Officer Josh Meier said. “This is the year things started working.”

Read more | BLOOMBERG